Generic Sweden Third Quarter 2023 Earnings: Revenues Beat Expectations

Generic Sweden (STO:GENI) Third Quarter 2023 Results

Key Financial Results

Revenue: kr34.8m (up 15% from 3Q 2022).
Net income: kr6.29m (up 18% from 3Q 2022).
Profit margin: 18% (in line with 3Q 2022).

earnings-and-revenue-growth — OM:GENI Earnings and Revenue Growth November 19th 2023

All figures shown in the chart above are for the trailing 12 month (TTM) period

Generic Sweden Revenues Beat Expectations

Revenue exceeded analyst estimates by 2.7%.

Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 8.5% growth forecast for the IT industry in Sweden.

Performance of the Swedish IT industry.

The company's shares are up 2.9% from a week ago.

Risk Analysis

You should always think about risks. Case in point, we've spotted 3 warning signs for Generic Sweden you should be aware of, and 1 of them is a bit concerning.

Valuation is complex, but we're helping make it simple.

Find out whether Generic Sweden is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

View the Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

View Profile